We also received our first patent allowance relating to PMN442 and PMN440, strengthening our position in the alpha-synuclein space ... and to not bind plaque or monomers. Oligomers are known ...

We also received our first patent allowance relating to PMN442 and PMN440, strengthening our position in the alpha-synuclein space ... bind toxic Aβ oligomers and to not bind plaque or monomers.

A new fluid biomarker for Parkinson’s disease (PD) was developed, offering a high-accuracy biological classification, ...

A new study reveals that the protein alpha-synuclein, known for its role in Parkinson’s disease, also contributes to the ...

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.

Researchers have identified a key enzyme driving forms of Parkinson’s, and have shown how blocking it restores normal function in animal and cell models – offering a promising new drug target for the ...

Scientists examined microscopic blobs of protein found in human cells has discovered that some morph from an almost honey-like substance to a hard candy-like solid. These mysterious droplets, known as ...

These mysterious droplets, known as biomolecular condensates, solidify when they carry a high proportion of the protein alpha-synuclein, the scientists reported. Clumps of alpha-synuclein are ...

"Developing drugs that target alpha-synuclein may be useful in both diseases," said senior author Vivek Unni, M.D., Ph.D., an associate professor of neurology in the OHSU School of Medicine.